RATIONALE-303

2/3L NSCLC

RATIONALE-303 Trial Design

Phase 3

Study Identifier:
BGB-A317-303, NCT03358875

Primary Endpoint: OS in ITT and PD-L1 ≥25% populations
Key Secondary Endpoints: ORR, DoR, PFS, HRQOL, safety



[a]Patients receiving tislelizumab were permitted to continue tislelizumab treatment beyond radio imaging progression if clinical benefit was seen in the absence of symptomatic deterioration and unacceptable toxicity per investigator's discretion.
2L=second line, 3L=third line, DoR=duration of response, ECOG PS=Eastern Cooperative Oncology Group performance status, HRQOL=health-related quality of life, IV=intravenous, NSCLC=non-small cell lung cancer, ORR=objective response rate, OS=overall survival, PD-1=programmed cell death protein 1, PD-L1=programmed death ligand 1, PFS=progression-free survival, Q3W=every 3 weeks, R=randomized.
ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03358875. Accessed October 9, 2025.